| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Smith & Nephew SNATS, Inc.$30.7
+0.3 (+0.99%)
C 50Pipeline Score MedTech · Commercial
Market Cap
13.00 B
EPS
1.44
P/E Ratio
21.28 $
Value Trade
41.29 M
2.62 %
Week
-6.06 %
1 Month
-15.43 %
3 Month
-5.68 %
6 Month
-30.66 %
5 Year
278.48 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.89 M
52 Week Range
28.40 - 38.79
% held by Insiders
0.06 %
% held by Institutions
7.56 %
Enterprise Value
15.77 B
Total Shares
426.11 M
Short %
0.77 %
Float Shares
425.87 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C50
Pipeline Score $2.8B
Pipeline ValueValuation Signal
10
Drugs Scored0.2x
rNPV / MCap Top 75%
Mid Cap (rank 229 of 911)
Percentile RankSmith & Nephew SNATS, Inc. carries a moderate pipeline score (50/100), with $3.3B risk-adjusted pipeline value, led by USL255 in Epilepsy (Phase 3), across $103B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| USL255 Small molecule | Epilepsy | Phase 3 | NCT01142193 | 48% | $1.3B | COMPLETED | 459 | - | - | Jan 1, 2013 | - | May 22, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
REGENETEN Bioinductive Implant | partial-thickness rotator cuff tears | — | 2026-04-09 | early recovery time was halved; Driving: 2.3 vs 5.1 weeks (p<0.001); Office work: 1.7 vs 3.6 weeks (p=0.009); Moderate-intensity household chores: 3.8 vs 8.4 weeks (p<0.001) Read More | Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,* Read More | |
REGENETEN Bioinductive Implant | partial-thickness rotator cuff tears | — | 2026-04-09 | early recovery time was halved; Driving: 2.3 vs 5.1 weeks (p<0.001); Office work: 1.7 vs 3.6 weeks (p=0.009); Moderate-intensity household chores: 3.8 vs 8.4 weeks (p<0.001) Read More | Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,* Read More | |
REGENETEN Bioinductive Implant | partial-thickness rotator cuff tears | — | 2026-04-09 | early recovery time was halved; Driving: 2.3 vs 5.1 weeks (p<0.001); Office work: 1.7 vs 3.6 weeks (p=0.009); Moderate-intensity household chores: 3.8 vs 8.4 weeks (p<0.001) Read More | Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,* Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SNN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SNN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SNN▲ +1%today
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
Smith+Nephew has announced the publication of new expert consensus guidelines for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions in Germany. This guidance aims to reduce post-surgical complications by identifying at-risk patients and providing a structured framework for clinical decision-making. The PICO 7 device is highlighted for its user-friendly features that support evidence-based practice.
Read more →SNN▲ +1%today
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
Smith+Nephew has announced new expert consensus guidelines for the use of single-use negative pressure wound therapy (sNPWT) in Germany. These guidelines aim to improve clinical outcomes and address economic challenges associated with postoperative wound complications. The recommendations are based on a risk score to guide the targeted use of sNPWT in high-risk patients, promoting better healthcare resource management.
Read more →SNNSmith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew has announced the successful completion of the first clinical cases using its next-generation CORI XT Handheld Robotics Platform for knee and shoulder arthroplasty. The platform aims to enhance surgical accuracy while maintaining efficiency in established workflows. Surgeons have reported positive experiences with the technology, indicating its potential to improve patient outcomes.
Read more →SNNSmith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew has launched the next generation LEAF Patient Monitoring System in the US, aimed at preventing hospital-acquired pressure injuries (HAPIs). This innovative platform utilizes a wearable sensor to monitor patient mobility and provide real-time updates, enhancing care protocols. The system has shown to reduce HAPIs significantly and offers substantial cost savings for healthcare facilities.
Read more →SNNSmith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Smith+Nephew is set to launch two new wound care products, ALLEVYN COMPLETE CARE Dressing and RENASYS EDGE tNPWT, at the EWMA Conference in May 2026. These innovations aim to enhance chronic wound management and improve patient outcomes. The products reflect the company's commitment to addressing the significant healthcare challenge posed by chronic wounds in Europe.
Read more →SNNSmith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
Smith+Nephew announced positive results from a randomized control trial for its REGENETEN Bioinductive Implant used in partial-thickness rotator cuff repairs. The trial demonstrated that patients experienced significantly shorter recovery times and high rates of tendon healing compared to traditional suture anchor repairs. The findings suggest a shift in treatment standards for rotator cuff injuries, enhancing patient outcomes.
Read more →SNNLife Unlimited Annual Report 2025 1 These non-IFRS financial measures are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS on pages 285–292. The images us
The Life Unlimited Annual Report 2025 was published by Smith & Nephew plc. The report highlights the company’s commitment to sustainability through the use of climate-neutral printing, responsible forest resource use, and the adoption of renewable energy sources. The Annual General Meeting is scheduled for May 6, 2026, where shareholders can address questions and vote. Financial results and dividend payments are outlined in the accompanying financial calendar for 2025.
Read more →SNNSmith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
Smith+Nephew will present its advanced handheld robotics and digital solutions at the AAOS Annual Meeting in New Orleans. The CORI Surgical System aims to enhance surgical accuracy and patient outcomes in joint arthroplasty. New trauma products and an expanded ASC offering will also be showcased, reflecting the company's commitment to innovation in orthopaedic care.
Read more →SNNSmith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
Smith+Nephew will showcase its advanced rotator cuff repair technologies at the AAOS 2026 Annual Meeting. The Tendon Seam Repair System and REGENETEN Bioinductive Implant are designed to enhance surgical outcomes and reduce re-tear rates. The AAOS has issued a strong recommendation for bioinductive implants, highlighting their effectiveness in improving patient outcomes.
Read more →SNNSmith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons
Smith+Nephew has entered into an exclusive distribution agreement with RMR Ortho for the A'TOMIC™ Nitinol Fixation System. This system is designed to enhance implant integrity and patient comfort, aligning with the company's focus on trauma and extremities. The partnership aims to leverage Smith+Nephew's established sales channels to deepen surgeon engagement and expand market access.
Read more →SNNSmith+Nephew signs distribution agreement with SI-BONE
Smith+Nephew has signed a distribution agreement with SI-BONE to enhance its offerings in pelvic fracture fixation procedures. This partnership focuses on the innovative iFuse TORQ portfolio, which includes advanced solutions for pelvic fractures and sacroiliac joint fusion. The collaboration aims to improve patient outcomes and strengthen Smith+Nephew's position in trauma procedures.
Read more →SNNSmith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
Smith+Nephew has completed the acquisition of Integrity Orthopaedics, enhancing its sports medicine shoulder repair offerings. The Tendon Seam™ system, designed to improve rotator cuff repair outcomes, features innovative technology that reduces re-tear rates. This acquisition positions Smith+Nephew as a leader in the RCR market, complementing its existing REGENETEN Bioinductive Implant.
Read more →SNNSmith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT
Smith+Nephew has published a comparative study showing that its PICO sNPWT device (-80 mmHg) outperforms PrevenaTM sNPWT (-125 mmHg) in reducing wound dehiscence and healthcare costs in orthopedic and cardiovascular surgeries. The study analyzed data from over 22,000 patients, indicating significant benefits in patient outcomes and economic efficiency. These findings support the growing evidence for the prophylactic use of negative pressure wound therapy.
Read more →SNNUFC® and Smith+Nephew announce multi-year extension of partnership
Smith+Nephew has extended its partnership with UFC, continuing as the Preferred Sports Medicine Technology Partner. This collaboration aims to enhance athlete safety through advanced medical technologies. A highlight of the partnership is the upcoming Smith+Nephew UFC Combat Sports Medicine Course, which will feature renowned medical experts. The partnership also allows for UFC athletes to represent Smith+Nephew in marketing efforts.
Read more →SNNSmith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant
Smith+Nephew announced that the AMA has established a Category I CPT code for its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027. This new code acknowledges the implant's clinical significance and aims to streamline reimbursement processes, enhancing patient access. The implant has shown an 87% reduction in the risk of total knee arthroplasty compared to traditional methods.
Read more →SNNSmith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
Smith+Nephew has announced new data supporting the ALLEVYN COMPLETE CARE Foam Dressing, which demonstrates a 93% absorption of mechanical energy, aiding in pressure injury prevention. This study, published in the International Wound Journal, highlights the dressing's ability to dissipate shear forces, potentially reducing the burden of pressure injuries on healthcare systems. The product is set to launch in the US market later this year.
Read more →SNNSmith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty
Smith+Nephew has launched its CORIOGRAPH Pre-Op Planning and Modeling Services for total shoulder arthroplasty in the U.S. This software enhances surgeons' ability to create patient-specific plans using advanced biomechanical simulations. The service aims to improve surgical outcomes and streamline the operating room experience. Surgeons have reported increased confidence in their planning capabilities.
Read more →SNNSmith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant
Smith+Nephew has announced new clinical evidence and market updates for its REGENETEN Bioinductive Implant, emphasizing its effectiveness in treating rotator cuff injuries. Recent guidelines from the AAOS highlight the implant's benefits, including lower re-tear rates. The company is also expanding its use to extra-articular ligament injuries, aiming to enhance patient access and treatment options.
Read more →SNNSmith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System
Smith+Nephew has launched the CENTRIO Platelet-Rich-Plasma System, designed to assist in the healing of chronic wounds by maintaining a moist environment. The system is suitable for various types of wounds and is supported by clinical trials. It will be showcased at the upcoming Symposium on Advanced Wound Care in Las Vegas. Smith+Nephew has partnered with Nuo Therapeutics for distribution in the U.S.
Read more →SNNSmith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option
Smith+Nephew has launched the Q-FIX KNOTLESS All-Suture Anchor, enhancing its fixation strength for soft tissue-to-bone applications in various joints. This new product builds on the success of the Q-FIX family, offering innovative features that aim to improve surgical reliability. Surgeons have praised the anchor's predictable deployment and impressive pullout strength, suggesting a shift in joint repair approaches.
Read more →SNNGlobal Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
Smith+Nephew has announced its sponsorship of select players at Wimbledon 2025, continuing its support from 2024. This initiative aims to highlight the company's advanced Sports Medicine technologies, which assist athletes in recovering from injuries. The partnership aligns with Smith+Nephew's mission of improving patients' lives through innovative medical solutions.
Read more →SNNSmith+Nephew’s new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing’ to trauma surgeons repairing tibial fractures
Smith+Nephew has launched the TRIGEN MAX Tibia Nailing System, designed for both stable and unstable tibial fractures. This system features side-specific nails that enhance anatomical fit and minimize soft tissue irritation. It aims to improve surgical efficiency and patient recovery, marking a significant advancement in lower extremity trauma care.
Read more →SNNAnnual Report 2024 Life Unlimited Contents $5,810m Group revenue 37.5¢ Unchanged Dividend per share +4.7% Reported +5.3% Underlying1 $657m +54.6% Operating profit 11.3% +360bps Operating profit margin $1,049m +8.2%
Smith & Nephew has released its Annual Report for 2024, showcasing a stable group revenue of $5.81 billion. The report highlights a substantial increase in operating profit by 54.6%, reflecting strong business performance. Additionally, the company has announced a 4.7% increase in dividends per share, demonstrating its commitment to returning value to shareholders. Key dates for the upcoming financial calendar include the Annual General Meeting and quarterly results reports.
Read more →SNNLife Unlimited Annual Report 2023 Contents Our performance Strategic Report Our performance IFC Who we are 2 Chair's statement 4 Chief Executive Officer's review 8 Our marketplace 14 Our business model 16 Key Performance
The 2023 Annual Report for Smith+Nephew (SNN) presents details on its sustainable practices, including carbon-neutral printing and eco-friendly production methods. Key dates for shareholder engagement are outlined, including the Annual General Meeting scheduled for May 1, 2024. The report also reflects the company's commitment to responsible resource use, showcasing efforts to minimize environmental impact through recycling and renewable energy. Additionally, it highlights ongoing transparency with stakeholders through notifications regarding dividends and meeting participation.
Read more →SNNSECURITIES AND EXCHANGE COMMISSION
Smith & Nephew plc has submitted its annual report for the fiscal year 2022 to shareholders as required by the Securities Exchange Act of 1934. The report is outlined in Exhibit 99.1 and includes comprehensive information about the company's performance. This submission is part of the company's regulatory obligations and demonstrates adherence to established guidelines.
Read more →Competitive Position
How SNN ranks across every disease it competes inCompetitive Position is a premium feature
See how SNN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial